Clinical Trial Update: Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating nab-paclitaxel plus gemcitabine as first-line therapy for cholangiocarcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-05-29